Aridis Pharma up on potential inhaled therapy for COVID-19

• Ultra-thinly traded nano cap Aridis Pharmaceuticals (NASDAQ:ARDS) perks up 7% premarket on light volume in reaction to its announcement of preclinical data supporting the potential efficacy of an inhalable formulation of AR-711, a neutralizing monoclonal antibody, for treating COVID-19.
• In a Syrian hamster study, the delivery of AR-711 directly to the lungs eliminated all detectable SARS-CoV-2 virus at substantially lower doses compared to parenteral administration.
• A clinical trial assessing AR-711, discovered from COVID-19 patients who had recovered from the infection, in non-hospitalized COVID-19 patients with mild-to-moderate symptoms should launch in H1 2021.
• https://seekingalpha.com/news/3623213-aridis-pharma-up-7-on-potential-inhaled-therapy-for-covidminus-19